Bottom line
Longevity talk starts by splitting two words. Lifespan is how many years you live. Healthspan is how many of those years you stay well enough to move and function 5.
The core aim of modern longevity science is not immortality. It is to extend lifespan and healthspan together. One topic page defines the second as the years that stay healthy and active 5.
Aging is not a timer. The World Health Organization describes it as the accumulation of many kinds of molecular and cellular damage over time. The pace is uneven, and it is only loosely tied to chronological age 12.
The field has already mapped why cells age. A 2013 review in *Cell* listed several "hallmarks of aging," including genomic instability, telomere attrition, epigenetic change, and loss of protein balance 10.
The most studied finding about centenarians is narrow. They do not avoid disease. They postpone the bad outcomes by 20 to 25 years 1.
The views broadly agree that the pace of aging can be changed by behavior. They differ on whether aging itself is a disease to treat, and on whether anti-aging drugs and tests are ready 469.
What it is
The opposite of healthspan is survival with disease. In the WHO phrasing, accumulated damage brings a gradual loss of physical and mental capacity and a rising risk of disease, until disability and death 12.
Geroscience bets that aging is the shared upstream of the chronic diseases. Slow aging itself, and heart attack, cancer, and dementia may arrive later together 1.
The aging researcher Nir Barzilai has discussed, in an interview, the TAME trial he leads. The trial uses metformin to test the idea of postponing several chronic diseases in older adults. It is a marker of the field moving from slogan to experiment 1. One essay is reserved about that path. Despite respect for Barzilai, the essay finds the evidence that metformin fights aging deeply unconvincing. Metformin is also an old, cheap drug, so trials of this kind struggle to find a funder 3.
On measurement, Horvath's 2013 method uses DNA methylation — the pattern of "switches" on genes — to estimate biological age. Later "aging clocks" grew from that approach 11.
One site turns the hallmarks into plain-language entries: loss of protein balance, weaker autophagy, chronic inflammation, each with a paper attached 8.
A comparison with a mature field shows the gap. Lowering apolipoprotein B (ApoB) lowers atherosclerotic risk, which is why ApoB is called a perfect biomarker. The speed of biological aging still has no equivalent measure 2.
Why it matters
Demography is pushing the science. The WHO estimates that by 2030 one in six people worldwide will be over 60. By 2050 the population over 60 is projected to double from about 1 billion in 2020 to 2.1 billion, and the population over 80 is projected to triple, to 426 million 12.
Living longer is only the numerator. If the extra years are spent in a hospital bed and a pill box, longevity becomes a longer ordeal. That is why healthspan became the central metric 5.
Measurement is the current bottleneck, and commerce is filling it. So-called aging clocks are already sold directly to the public, often for several hundred dollars a test 29.
Researchers in one discussion are restrained about that. The field is closer than it was fifteen or twenty years ago, but it is still short of predicting an individual's aging path with precision. Optimism inside and outside the industry may be running ahead of the evidence 2.
For a person, the most useful output may be a change of question. Instead of "can I live to 100," ask whether at 80 you can still buy groceries, climb stairs, and remember the names of your family 1.
Different perspectives
Main positions
One view translates longevity into prevention. Nothing matters more than prevention of chronic disease, and prevention after a heart attack is already late. Secondary prevention does not count as prevention 1.
The same view returns to centenarians. Their causes of death look strikingly like everyone else's: atherosclerosis, heart attack, pneumonia. The point is a shift in time 1.
A German study of autopsies in a thousand centenarians is cited there. The conclusion is almost wry: centenarians are not a special case. They die of the same diseases, only 30 years later 1.
On measurement, Matt Kaeberlein is brought in. Lipid science has a marker with a clear causal story, ApoB. Aging still has no consensus marker, and the rush of commercial clocks is a reason for caution 2.
Another conversation with Kaeberlein goes into nutrition and aging. That episode separates "nutrition interventions that reliably extend life in mice" from "concerns about whether they work in people" 4. Protein and rapamycin push the mTOR pathway in opposite directions. That opposition is the molecular root of the argument over how much protein to eat 4.
The practical landing point stays plain: very early prevention, in exchange for five to ten more years of life 1.
This theme is concentrated in two representative conversations, drawn from a broader set of episodes on the subject 5.
The episode with Harvard geneticist David Sinclair is framed as a cellular and molecular account of why aging happens and how it might be slowed or reversed 6. The timeline includes "aging as a disease," "what causes aging: the epigenome," the Horvath clock, and "which behaviors extend life" 6.
Sinclair's position in that conversation is direct. Aging is a process that can be acted on, not background noise to accept 6.
The episode with UCSF psychiatry professor Elissa Epel focuses on stress and aging: how stress touches cellular aging and telomeres, and how breathing practice, mindfulness, exercise, and cognitive reframing can intervene 7.
Papers cited on that episode sit on both sides of the ledger. One is a mechanistic paper on stress and telomere shortening. Another asks whether mindfulness can slow cellular aging 7.
Taken together, those episodes treat aging as biology, and behavior as a lever.
Two full topic pages carry the science, in a treatment close to a textbook 89.
The hallmarks page takes the mechanisms one by one. Protein balance and aging cause each other. Weaker autophagy lets damaged proteins and organelles pile up 8. Age-related autophagy is hard to capture with a single marker, because the steps affected and the size of the drop differ by tissue 8.
The biological-age clocks page evaluates the newer clocks. GrimAge's second generation folds methylation proxies for high-sensitivity C-reactive protein and HbA1c into death-risk prediction. In validation analyses, OMICmAge associates strongly with chronic disease and mortality 9.
Those pages also stress that aging is not one thing. Functional age, molecular age, and organ age are separate. A blood-based clock can miss tissue-specific aging 9.
On consumer tests, the page treats epigenetic age testing as a motivation tool, not a diagnostic conclusion, and it repeats that newer clocks still need broad validation across populations, tissues, interventions, and outcomes 9.
Where views agree and differ
Three points of agreement:
- The pace of aging can be changed. It is not fixed at birth 47.
- Healthspan comes before lifespan alone. Compressing the years lived with disease is a shared goal 13.
- The action levers that keep appearing on these pages are exercise, nutrition, and stress management 17.
Disagreement one: is aging a "disease"? Sinclair's episode puts "Aging as a Disease" on the agenda 6. Kaeberlein, and the view beside him, stress that markers and intervention evidence are not in place, and they lean toward solving measurement first 2.
Disagreement two: how far anti-aging molecules — NAD precursors, rapamycin, metformin, and the like — are from the public. Kaeberlein's episode sets "nutrition interventions that reliably extend life in mice" beside "concerns about effectiveness in people" 4. Barzilai's TAME trial is meant to supply human evidence, and it spent ten years looking for funding 3. In an interview, Sinclair talks openly about his own practice, and the timeline sets out metformin, resveratrol, and NAD precursors 6.
PearHealth's synthesis
We take two points of agreement: healthspan first, and behavior as the largest lever. Both can start without a new drug 17.
We are reserved about consumer biological-age tests. As a motivation tool they are interesting. As a medical conclusion they are early 29.
We are equally reserved about "longevity supplements." Trials with human endpoints are missing, and that layer of evidence will not fill in soon 34.
A caution: this field sits very close to commerce. Clocks are for sale, supplements are for sale, and celebrity protocols circulate. Reading any study in this area with the funder and the commercial ties in view is basic literacy here 9.
We also reject the fatalist flip side. Most genes hand out probabilities, not verdicts. That point is the same one made in the family-history article 13.
How strong is the evidence
"Aging has describable cellular mechanisms" is firm. The hallmarks review is used across the field as a map 10.
"Methylation can estimate biological age" is also firm. Horvath's method replicates across several tissues 11. The jump from "the measurement is accurate" to "changing the number changes fate" is still the missing one 9.
"Centenarians get sick later" comes from population observation. The direction is consistent. The mechanism is not fully taken apart 1.
"Behavior extends healthspan" splits cleanly by layer. Exercise and not smoking have large population-level evidence. For "this way of eating extends life," Kaeberlein's episode keeps the mouse evidence separate from the concerns in humans 4.
Randomized trials of longevity interventions with death or disability as the endpoint barely exist. TAME is the closest attempt, and even its funding took ten years to assemble 3.
"Stress speeds cellular aging" has support from human samples and mechanism studies. The causal chain is still being filled in 7.
What you can do
A common translation of "ask for five more healthy years" is today's behavior.
- Put regular exercise first. Barzilai's summary of the lessons is that for most of us the answer is still exercise and nutrition 1.
- Sleep and stress management are not mysticism. Epel's toolbox — breathing practice, mindfulness, exercise, reframing the story — can be practiced in ordinary days 7.
- Do not smoke, and keep alcohol and body weight in check. Accelerated aging with obesity is on the episode agenda 6.
- Before chasing a biological-age number, look after the "hard markers": ApoB, blood pressure, and glucose, the ones with a clear causal story 2.
Questions worth raising with a clinician:
- Where do my ApoB, blood pressure, and HbA1c sit, and is a target worth setting 2?
- Is a biological-age test worth the money? Treating it as a motivation tool and treating it as a medical conclusion are very different 9.
- If I change starting now, is it still in time? How late-start interventions perform is worth the conversation 4.
Common misconceptions
Misconception one: longevity means living as long as possible. Without the healthspan dimension, what gets extended may be the years lived with disease 15.
Misconception two: centenarians have a body that does not age. Their causes of death look like everyone else's. The timing is later 1.
Misconception three: a biological-age test is a medical diagnosis. For now it is closer to a motivation tool, and the newer clocks are still being validated 29.
Misconception four: "longevity drugs" have arrived. Human endpoint evidence is missing, and the amounts and settings used in research do not transfer to daily life. Even metformin, the best-known candidate, is judged in one essay as evidence that does not pass 34.
Misconception five: aging is written in the genes, so nothing you do matters. Behavior and environment clearly change the pace. That is the shared floor across these views 47.
How it connects to your blood work
No routine blood test measures "the speed of aging." Epigenetic clocks need a dedicated methylation assay, and interpretation is not yet standardized 911.
Several threads of aging science do have anchors in ordinary labs:
- Apolipoprotein B (apob): one account uses it as the contrast case of a perfect biomarker. Lowering it lowers atherosclerotic risk 2.
- HbA1c (hba1c): GrimAge2 folds a methylation proxy for it into death-risk prediction. Metabolic health and aging are tightly tied 9.
- High-sensitivity C-reactive protein (hs-crp): an inflammation signal also folded into GrimAge2, reflecting chronic low-grade inflammation 9.
- Insulin-like growth factor 1 (igf-1): the growth hormone–IGF-1 pathway is a hub that longevity research keeps returning to, and it is a topic on Kaeberlein's episode 4.
Looking after these is closer to the field's current conclusion than chasing a single "biological age" score.